



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

RAJOPADHYE ET AL.

ATTORNEY DOCKET NO.: DM-6958

APPLICATION NO.: 09/281,474

GROUP ART UNIT: 1616

FILED: MARCH 30, 1999

EXAMINER: JONES, D. L.

CONFIRMATION NO.: .7274

FOR: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS

Commissioner of Patents and Trademarks
Washington, D.C. 20231

TECH CENTER 1600/2900

OCT 24 2002

RECEIVED

24/B
BUTTS
11-02AMENDMENT AND RESPONSE UNDER 37 C.F.R. 1.111

Sir:

In response to the Office Action dated July 2, 2002, please amend the above-identified application as follows and consider the following remarks.


IN THE CLAIMS:

Please cancel claims 36-47 and 51.

Please replace claims 2, 3, 12, 13, 19, 20, 27, 28, and 31 as follows.

2. (Amended) A compound according to Claim 1, wherein the targeting moiety is a peptide or a mimetic thereof and the receptor is $\alpha_v\beta_3$ and the linking group is present between the targeting moiety and chelator.

3. (Amended) A compound according to Claim 2, the compound is of the formula:



wherein, Q is a peptide independently selected from the group:

